Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Interest & Investment Income (2020 - 2025)

Lyell Immunopharma's Interest & Investment Income history spans 6 years, with the latest figure at $3.3 million for Q3 2025.

  • For Q3 2025, Interest & Investment Income fell 45.25% year-over-year to $3.3 million; the TTM value through Sep 2025 reached $15.3 million, down 41.58%, while the annual FY2024 figure was $24.1 million, 2.62% up from the prior year.
  • Interest & Investment Income for Q3 2025 was $3.3 million at Lyell Immunopharma, roughly flat from $3.3 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $7.1 million in Q4 2023 and bottomed at $218000.0 in Q2 2021.
  • The 5-year median for Interest & Investment Income is $3.5 million (2022), against an average of $3.5 million.
  • The largest annual shift saw Interest & Investment Income tumbled 88.41% in 2021 before it soared 1032.75% in 2023.
  • A 5-year view of Interest & Investment Income shows it stood at $323000.0 in 2021, then surged by 969.04% to $3.5 million in 2022, then skyrocketed by 105.15% to $7.1 million in 2023, then crashed by 30.55% to $4.9 million in 2024, then crashed by 33.62% to $3.3 million in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Interest & Investment Income are $3.3 million (Q3 2025), $3.3 million (Q2 2025), and $3.9 million (Q1 2025).